Lumida
/CLOV
⌘K
Clover Health Investments Corp

Clover Health Investments Corp

CLOV
$4.82USD+2.34%+0.11 today

MARKET CAP

2.6B

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$2
$6

AI Summary

Stalk
StalkMedium

CLOV has posted a decisive momentum breakout above the consolidation high with volume and EMAs aligned, but price is extended and RSI is overbought. In a Stage 2 advancing structure, medium-term bias remains bullish. We defer execution and await a shallow pullback into the rising 9- and 20-EMA near the $4.45–$4.60 support zone before participating in line with the Momentum + EPS strategy.

  • Q2 revenue $743.2M (+55.6% YoY) and EPS $0.05 beats estimates.
  • GAAP net income $28M vs $11M loss year-ago; adj. EBITDA +139%.
  • Forward P/E of 82 signals high valuation risk.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.5B$1.1B$1.3B$1.4B$1.9B
YoY %-25.5%+15.0%+8.8%+40.3%
P / Sales1.0x0.4x0.4x1.1x0.6x
EV / Sales1.1x0.7x0.5x1.2x0.7x
Gross Profit, Adj.$-79.2M$103.5M$256.0M$364.8M$355.9M
YoY %+230.7%+147.3%+42.5%-2.4%
Margin %-5.4%9.4%20.3%26.6%18.5%
EV / Gross Profit-20.8x7.7x2.5x4.4x3.8x
EBITDA, Adj.$-635.5M$-287.0M$-181.1M$-46.7M$-85.7M
YoY %+54.8%+36.9%+74.2%-83.7%
Margin %-43.2%-26.2%-14.4%-3.4%-4.5%
EV / EBITDA-2.6x-2.8x-3.5x-34.1x-15.8x
EBIT$-637.0M$-286.7M$-205.3M$-45.7M$-85.5M
YoY %+55.0%+28.4%+77.7%-87.0%
Margin %-43.3%-26.1%-16.3%-3.3%-4.4%
EV / EBIT-2.6x-2.8x-3.1x-34.7x-15.9x
Net Income$-587.8M$-339.6M$-213.4M$-43.0M$-85.5M
YoY %+42.2%+37.2%+79.8%-98.9%
Net Margin-39.9%-31.0%-16.9%-3.1%-4.4%
EPS (GAAP)-$1.42-$0.71-$0.44-$0.09-$0.17
YoY %+50.0%+38.0%+79.5%-88.9%